Finn
TWST Life Sciences Tools · Synthetic biology · NGS · AI drug discovery · Thesis updated November 15, 2026

Twist hits breakeven as AI demand surges, but price matters

01 Running thesis

Breakeven achieved, but the investment cycle continues

Twist delivered a highly positive close to fiscal 2026. Q4 revenue grew 28% year over year to $126.6 million. More importantly, the company achieved its long-standing goal of reaching positive adjusted EBITDA, posting a $2.2 million gain. The bull case is now grounded in proven operational leverage and massive secular tailwinds from AI drug discovery, which saw revenue surge 175% for the full year.

Next-generation sequencing (NGS) applications also successfully re-accelerated to 24% growth in the quarter. This provides a stable, high-growth second engine alongside the fast-expanding DNA synthesis business. Management expects AI-driven revenue to reach $100 million in fiscal 2027, driven by customers moving from pilot programs to recurring, multi-million dollar discovery orders.

The bear case now centers on execution risk during a period of heavy capacity expansion. The company is guiding for $75 million in capital expenditures for fiscal 2027 to build out capacity ahead of demand. This will result in a 2 to 3 percent gross margin headwind due to depreciation. If Twist fails to fill this new capacity with the anticipated demand, profitability will suffer and the company could return to burning cash.

Nov 2026▲Q4 FY26 results showed the company hitting adjusted EBITDA breakeven. AI drug discovery revenue surged 175% for the year, and NGS re-accelerated to 24% growth.
Aug 2026▲Q3 FY26 results showed a 23.2% increase in total revenue, driven by a 39% surge in DNA synthesis and protein solutions. Management noted increased confidence in triple-digit order growth for AI-enabled discovery.
May 2026▲The Q2 FY26 10-Q confirmed 19% revenue growth to $110.7 million. DNA synthesis and protein solutions grew 28%, while NGS applications grew 12%, supporting the view that both growth engines are working.
May 2026▲The Q2 earnings call strengthened the bull case. Management said AI-driven demand had broadened to dozens of accounts and guided NGS applications back to 20% growth by Q4 FY26.
Feb 2026→The Q1 FY26 10-Q confirmed the earlier earnings story and did not add material new risk factors. It supported the view that NGS was recovering while DNA synthesis stayed strong.
Feb 2026▲Q1 commentary showed repeat large orders from AI-related customers and said the prior major NGS customer issue had passed. Management also raised full-year revenue guidance by more than the Q1 beat.
Feb 2026▲The Q1 FY26 filing showed revenue growth of 16.9% to $103.7 million and gross margin of 52.0%. That supported the path toward adjusted EBITDA breakeven.
Nov 2025▲Twist introduced AI-enabled drug discovery as a bigger revenue driver and described MRD Express as a new cancer diagnostics product. The same update also flagged a near-term NGS slowdown from a major customer transition.
02 Business model

A DNA factory for drug builders

Twist makes money by using its silicon-based DNA synthesis platform to produce synthetic DNA at high scale. Customers buy genes, gene fragments, oligo pools, antibody discovery work, and sequencing workflow tools. The basic idea is simple: scientists design DNA on a computer, Twist builds it, and the customer uses it in research, diagnostics, or drug discovery.

The higher-value part of the model involves moving customers from basic DNA orders into full workflows. AI drug discovery companies are a key example. Many of them need a fast loop: design a molecule, build the DNA, test the protein, learn from the result, then repeat. Twist sells into several steps of that loop and recently launched cell-free protein screening to speed up the process.

The model breaks if speed, quality, or cost advantages fade. It also breaks if newer demand is more one-time than repeat. That is why the mix of AI revenue matters. Recurring discovery work is much better than large model-building orders that do not repeat.

03 Product portfolio

From genes to cancer panels

Steady

Synthetic genes and gene fragments

These are core DNA building blocks for research and drug discovery. They help fill the platform and bring customers into the broader product set.

Growth engine

Protein solutions and antibody discovery

This area helps researchers move from DNA design to protein testing. It includes the new Twist Express Screening Antibodies, which deliver proteins in just five days.

Growth engine

NGS applications

Twist sells tools such as target enrichment panels for clinical and research workflows. This segment re-accelerated to 24% growth in the latest quarter.

Option

MRD Express

A newly launched product offering individualized tumor-informed panels manufactured at scale, designed specifically for the cancer monitoring market.

Steady

Oligo pools

Large sets of short DNA sequences used in experiments and screening. They support the high-throughput side of Twist's platform.

04 Business segments

Two engines, growing fast

NGS applications52%growing fast
DNA synthesis and protein solutions48%growing fast

Segment mix is from Q4 FY26, the quarter ended September 30, 2026. NGS applications accounted for roughly 52% of revenue, while DNA synthesis and protein solutions accounted for 48%. Both segments grew over 20% year over year.

05 Risk factors

What could break the thesis

Heavy capacity investments pressure margins

High impact · Medium odds

Management guided for $75 million in capital expenditures for fiscal 2027. This buildout will cause a 2 to 3 percent gross margin headwind due to depreciation. If demand fails to fill this new capacity, profitability will suffer.

We watchGross margin trends, adjusted EBITDA results, and capital expenditure spending throughout fiscal 2027.

AI orders prove lumpy

High impact · Medium odds

AI-enabled drug discovery is now a massive growth engine, hitting $59.1 million in fiscal 2026. The open question is whether future revenue is recurring discovery work or large, one-time model-training orders.

We watchManagement commentary on repeat orders, customer count, and the mix of recurring AI workflows versus one-time projects.

MRD Express adoption lags

Medium impact · Medium odds

MRD Express is a key new NGS product for cancer monitoring. The product is commercially launched, but the revenue profile and customer adoption curve are still unproven in a competitive diagnostic market.

We watchEarly customer adoption, pricing stability, and gross margin commentary for MRD Express.

Less diversification after data storage spinout

Medium impact · Low odds

Twist spun out its DNA data storage work into Atlas Data Storage in May 2025. The filing risk is that Twist may not receive all expected benefits if Atlas does not commercialize the technology well.

We watchUpdates on Atlas Data Storage milestones and any related financial benefit or impairment risk.
06 Quick answers

In one breath

What does Twist Bioscience actually sell?

Twist sells synthetic DNA products, protein and antibody services, and tools used in next-generation sequencing. Its platform helps researchers and drug developers build and test biological designs faster.

Why is AI drug discovery important for Twist?

AI drug discovery companies need to test many designs in the lab. Twist can supply the DNA and related protein work that lets those companies run the design, build, test, learn cycle rapidly.

Is Twist Bioscience profitable?

The company reached adjusted EBITDA breakeven in Q4 FY26. However, heavy capital expenditure plans for fiscal 2027 mean the company will still face significant margin and cash flow pressures.

What is the biggest thing to watch next?

Watch whether the company can maintain adjusted EBITDA profitability throughout fiscal 2027 despite taking on $75 million in capital expenditures to build new capacity.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Twist Bioscience Q3 FY2026 Form 10-Q
  2. Twist Bioscience Q4 FY2026 earnings call transcript
  3. Twist Bioscience Q2 FY2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Twist Bioscience Corporation in Finn's Diagnostics & Research industry ranking.

Get started with Finn today